Kala Pharmaceuticals(KALA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update KALA's innovative pipeline is based on its proprietary mesenchymal stem cell secretome (MSC- S) platform. KALA believes the multifactorial mechanism of action of its MSC-S platform technology may enable it to generate product candidates for a range of rare, ocular diseases and is evaluating the potential development of this technology for multiple rare, front- and back- of-the-eye diseases. KALA's lead product ...